Tirzepatide for weight loss in adults with congenital heart disease
Part of Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether the medicine tirzepatide can help adults who are overweight or obese and have congenital heart disease (a heart condition present from birth) lose weight safely. The medicine may also improve heart health and metabolism. It is for people who have already tried diet and exercise for at least a year without much weight loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a congenital heart condition
- Your body mass index (BMI) is between 30 and 40 (a measure of body size based on height and weight)
- You have not taken any weight-loss medication or had weight-loss surgery before
- Your weight has been stable (not changing by more than 5%) for the past 3 months
- You are not currently smoking, and you do not have diabetes, severe heart failure, certain heart rhythm problems, or other serious conditions
- If you can get pregnant, you must agree to use highly effective birth control during the study and for 8 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the ability to exercise and daily function in people who have heart failure with reduced pumping strength and are overweight or obese.
This study tests whether combining a weight-loss medication called tirzepatide (also known as Mounjaro) with a supervised exercise program helps people lose weight and improve their overall health. You'll be in the study for about four months, and you'll get support and monitoring.
This trial tests if the weight loss medication tirzepatide can help young adults (18–40) with obesity and high blood pressure lower their blood pressure. It compares standard care to weight loss with tirzepatide.
This study looks at how well the medicine tirzepatide works in real life for adults who are overweight (BMI 30 or more) and have prediabetes or type 2 diabetes. It aims to see if the medicine helps control blood sugar and weight, and it's important that you have had a recent eye exam before starting.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.